Amendments to the Claims

The listing of claims will replace all prior versions and listings of claims in the application.

Listing of the Claims:

Claim 1 (currently amended): A ~~pharmaceutical composition~~ liquid formulation for parenteral administration comprising tartaric acid and a somatostatin analogue comprising ~~the~~ an amino acid sequence of formula I

-(D/L)Trp-LYs-X_1 -X_2 - I

wherein X_1 is a radical of formula (a) or (b)



(a)



(b)

wherein R_1 is optionally substituted phenyl,

R_2 is $-Z_1-CH_2-R_1$, $-CH_2-CO-O-CH_2-R_1$,



or



wherein Z_1 is O or S, and

X_2 is an α-amino acid having an aromatic residue on the C_α side chain, or an amino acid unit selected from Dab, Dpr, Dpm, His,(Bzl)HyPro, thienyl-Ala, cyclohexyl-Ala and t-butyl-Ala, the residue Lys of said sequence corresponding to the residue Lys^9 of the native somatostatin-14

in free form, salt form, or protected form ~~and tartaric acid~~.

Claim 2 (currently amended): A ~~composition~~ liquid formulation according to claim 1 wherein the somatostatin analogue is a compound of formula II



II

wherein the configuration at C-2 is (R) or (S) or a mixture thereof, and

wherein R is NR_1R_2-C_{2-6}alkylene or guanidine-C_{2-6}alkylene, and each of R_1 and R_2 independently is H or C_{1-4}alkyl,

in free form, salt form or protected form.

Claim 3 (currently amended): A ~~composition~~ liquid formulation according to claim 1 wherein the compound of the somatostatin analogue is in aspartate di-salt form.

Claim 4 (currently amended): A ~~composition~~ liquid formulation according to claim 1 wherein the composition is adjusted to a pH of about 4 to about 4.5.

Claim 5 (currently amended): A ~~composition~~ liquid formulation for parenteral administration buffered at a pH of about 4 to about 4.5 and comprising as active ingredient cyclo[{4-(NH_2-C_2H_4-NH-CO-O-)Pro}-Phg-DTrp-Lys-Tyr(4-Bzl)-Phe] or a pharmaceutically acceptable salt thereof.

Claim 6 (currently amended): A ~~composition~~ liquid formulation according to claim 5 wherein the composition is buffered by an acetate/acetic acid, lactate/ lactic acid, or Glycin / HCl buffer.

Claim 7-9 (canceled):

Claim 10. (Withdrawn): A compound of formula III



III

wherein R is NR_1R_2-C_{2-6}alkylene or guanidine-C_{2-6}alkylene, and
each of $R_1$and R_2 independently is H or C_{1-4}alkyl,
in free form, in salt form or complex form, or in protected form, e.g. cyclo[{4-(NH_2-C_2H_4-NH-CO-O-)Pro}-DPhg-DTrp-Lys-Tyr(4-Bzl)-Phe].

11. (currently amended) A ~~pharmaceutical composition~~ liquid formulation according to Claim 1 wherein the somatostatin analogue is cyclo[{4-(NH_2-C_2H_4-NH-CO-O-)Pro}-Phg-DTrp-Lys-Tyr(4-Bzl)-Phe] or a pharmaceutically acceptable salt thereof.

12. (currently amended) A ~~pharmaceutical composition~~ liquid formulation according to claim 3 wherein the compound of the somatostatin analogue is cyclo[{4-(NH_2-C_2H_4-NH-CO-O-)Pro}-Phg-DTrp-Lys-Tyr(4-Bzl)-Phe] or a pharmaceutically acceptable salt thereof.

13. (currently amended) A method of treating Cushing's Disease comprising administering a ~~pharmaceutical composition~~ liquid formulation according to Claim 11.

14. (currently amended) A method of treating Cushing's Disease comprising administering a ~~pharmaceutical composition~~ liquid formulation according to Claim 12.